Gemcabene 900 mg
DrugGemcabene 900 mg once daily (QD)
NCT Number: NCT02586168
The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Gemcabene 900 mg once daily (QD)
Placebo
Time frame: 4 weeks
Time frame: 4 weeks
Time frame: 4 weeks
Clinically Significant Changes
Time frame: 4 weeks
Clinical Laboratory Abnormalities
NeuroBo Pharmaceuticals Inc.
Industry
The Effect of Gemcabene (CI-1027) on Insulin Sensitivity in Nondiabetic Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04264897
Aging, Chronic Disease
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT05764200
Glucose Metabolism Disorders, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Maastricht, Netherlands
View Trial DetailsNCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial DetailsNCT03479671
Diabetes Mellitus, Diabetes Mellitus, Type 2
Philadelphia, Pennsylvania, United States
View Trial Details